4//SEC Filing
Londei Marco 4
Accession 0001209191-19-034870
CIK 0001370053other
Filed
Jun 4, 8:00 PM ET
Accepted
Jun 5, 5:54 PM ET
Size
14.0 KB
Accession
0001209191-19-034870
Insider Transaction Report
Form 4
ANAPTYSBIO INCANAB
Londei Marco
Chief Medical Officer
Transactions
- Sale
Common Stock
2019-06-04$72.45/sh−6,009$435,359→ 26,428 total - Sale
Common Stock
2019-06-04$74.50/sh−2,003$149,219→ 22,377 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2019-06-04−10,060→ 0 totalExercise: $0.70Exp: 2024-10-27→ Common Stock (10,060 underlying) - Exercise/Conversion
Common Stock
2019-06-04$0.70/sh+10,060$7,042→ 32,437 total - Sale
Common Stock
2019-06-04$73.43/sh−2,048$150,384→ 24,380 total
Footnotes (6)
- [F1]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.04 to $73.98 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.085 to $74.78 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The stock option vested and became exercisable as to 25% of the shares subject to the option on October 24, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- [F6]The Reporting Person also holds (i) additional options to purchase up to an aggregate of 224,148 shares of common stock, which options vest according to their terms, and (ii) 22,377 shares of common stock held directly.
Documents
Issuer
ANAPTYSBIO INC
CIK 0001370053
Entity typeother
Related Parties
1- filerCIK 0001654500
Filing Metadata
- Form type
- 4
- Filed
- Jun 4, 8:00 PM ET
- Accepted
- Jun 5, 5:54 PM ET
- Size
- 14.0 KB